{"success":true,"data":{"pressRelease":{"id":"19986","rtpr_id":"nACScKXkca","ticker":"SLNO","exchange":"NASDAQ","all_tickers":["SLNO"],"title":"Soleno Therapeutics 24 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Soleno Therapeutics, Inc. - SLNO","author":"ACCESSWIRE","published_at":"2026-05-04T23:00:00.925Z","article_body":"NEW YORK CITY, NY AND NEW ORLEANS, LA / ACCESS Newswire\n(https://www.accessnewswire.com/) / May 4, 2026 / Kahn Swick & Foti, LLC\n(https://pr.report/l94i) (\"KSF\") and KSF partner, the former Attorney General\nof Louisiana, Charles C. Foti, Jr., remind investors that they have until May\n5, 2026 to file lead plaintiff applications in a securities class action\nlawsuit against Soleno Therapeutics (https://pr.report/l94j), Inc. (\"Soleno\"\nor the \"Company\") (NasdaqCM:SLNO), if they purchased or otherwise acquired the\nCompany's securities between March 26, 2025 and November 4, 2025, inclusive\n(the \"Class Period\"). This action is pending in the United States District\nCourt for the Northern District of California.\n\nWhat You May Do\n\nIf you purchased securities of Soleno and would like to discuss your legal\nrights and how this case might affect you and your right to recover for your\neconomic loss, you may, without obligation or cost to you, contact KSF\nManaging Partner Lewis Kahn toll-free at 1-877-515-1850 or via email\n(lewis.kahn@ksfcounsel.com), or visit\nhttps://www.ksfcounsel.com/cases/nasdaqcm-slno/ to learn more. If you wish to\nserve as a lead plaintiff in this class action by overseeing lead counsel with\nthe goal of obtaining a fair and just resolution, you must request this\nposition by application to the Court by May 5, 2026.\n\nAbout the Lawsuit\n\nSoleno and certain of its executives are charged with failing to disclose\nmaterial information during the Class Period, violating federal securities\nlaws.\n\nThe alleged false and misleading statements and/or omissions include, but are\nnot limited to, that: (i) The Phase 3 clinical trial program for DCCR, the\nCompany's only commercial product (for the treatment of hyperphagia in\nindividuals afflicted with Prader-Willi syndrome or \"PWS\"), systematically\nminimized, mischaracterized, and/or failed to disclose substantial evidence of\npotential safety concerns associated with its administration, including\nindications of excessive fluid retention among clinical trial participants;\n(ii) as a result, the administration of DCCR to treat hyperphagia in\nindividuals with PWS posed materially greater safety risks than disclosed by\nthe Company; and (iii) consequently, DCCR had materially lower commercial\nviability and undisclosed risks related to the likelihood of significant and\nwidespread adverse events after its commercial launch, including risks related\nto patient discontinuation rates, lower patient adoption, prescriber\nreluctance, adverse regulatory action, and potential reputational and legal\nfallout.\n\nThe case is City of Pontiac Police and Fire Retirement System v. Soleno\nTherapeutics, Inc., No. 26-cv-01979.\n\nAbout Kahn Swick & Foti (https://pr.report/l94l), LLC\n\nKSF, whose partners include former Louisiana Attorney General Charles C. Foti,\nJr., is one of the nation's premier boutique securities litigation law firms.\nThis past year, KSF was ranked by SCAS among the top 10 firms nationally based\nupon total settlement value. KSF serves a variety of clients, including public\nand private institutional investors, and retail investors - in seeking\nrecoveries for investment losses emanating from corporate fraud or malfeasance\nby publicly traded companies. KSF has offices in New York, Delaware,\nCalifornia, Louisiana, Chicago, and a representative office in Luxembourg.\n\nTOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services\n\nTo learn more about KSF, you may visit www.ksfcounsel.com.\n\nContact:\n\n(https://app.accessnewswire.com/imagelibrary/b8decb8d-ef1e-4840-b938-8b83908eea3c/image.png)\n\nKahn Swick & Foti, LLC\nLewis Kahn, Managing Partner\nlewis.kahn@ksfcounsel.com\n1-877-515-1850\n1100 Poydras St., Suite 960\nNew Orleans, LA 70163\n\nCONNECT WITH US: Facebook (https://pr.report/l94n) || Instagram\n(https://pr.report/l94o) || YouTube (https://pr.report/l94p) || TikTok\n(https://pr.report/l94q) || LinkedIn (https://pr.report/l94r)\n\nSOURCE: Kahn Swick & Foti, LLC\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/soleno-therapeutics-24-hour-deadline-alert-kahn-swick-and-foti-l-1163731)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACScKXkca","title":"Soleno Therapeutics 24 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Soleno Therapeutics, Inc. - SLNO","author":"ACCESSWIRE","ticker":"SLNO","created":"2026-05-04T23:00:00.925Z","tickers":["SLNO"],"exchange":"NASDAQ","article_body":"NEW YORK CITY, NY AND NEW ORLEANS, LA / ACCESS Newswire\n(https://www.accessnewswire.com/) / May 4, 2026 / Kahn Swick & Foti, LLC\n(https://pr.report/l94i) (\"KSF\") and KSF partner, the former Attorney General\nof Louisiana, Charles C. Foti, Jr., remind investors that they have until May\n5, 2026 to file lead plaintiff applications in a securities class action\nlawsuit against Soleno Therapeutics (https://pr.report/l94j), Inc. (\"Soleno\"\nor the \"Company\") (NasdaqCM:SLNO), if they purchased or otherwise acquired the\nCompany's securities between March 26, 2025 and November 4, 2025, inclusive\n(the \"Class Period\"). This action is pending in the United States District\nCourt for the Northern District of California.\n\nWhat You May Do\n\nIf you purchased securities of Soleno and would like to discuss your legal\nrights and how this case might affect you and your right to recover for your\neconomic loss, you may, without obligation or cost to you, contact KSF\nManaging Partner Lewis Kahn toll-free at 1-877-515-1850 or via email\n(lewis.kahn@ksfcounsel.com), or visit\nhttps://www.ksfcounsel.com/cases/nasdaqcm-slno/ to learn more. If you wish to\nserve as a lead plaintiff in this class action by overseeing lead counsel with\nthe goal of obtaining a fair and just resolution, you must request this\nposition by application to the Court by May 5, 2026.\n\nAbout the Lawsuit\n\nSoleno and certain of its executives are charged with failing to disclose\nmaterial information during the Class Period, violating federal securities\nlaws.\n\nThe alleged false and misleading statements and/or omissions include, but are\nnot limited to, that: (i) The Phase 3 clinical trial program for DCCR, the\nCompany's only commercial product (for the treatment of hyperphagia in\nindividuals afflicted with Prader-Willi syndrome or \"PWS\"), systematically\nminimized, mischaracterized, and/or failed to disclose substantial evidence of\npotential safety concerns associated with its administration, including\nindications of excessive fluid retention among clinical trial participants;\n(ii) as a result, the administration of DCCR to treat hyperphagia in\nindividuals with PWS posed materially greater safety risks than disclosed by\nthe Company; and (iii) consequently, DCCR had materially lower commercial\nviability and undisclosed risks related to the likelihood of significant and\nwidespread adverse events after its commercial launch, including risks related\nto patient discontinuation rates, lower patient adoption, prescriber\nreluctance, adverse regulatory action, and potential reputational and legal\nfallout.\n\nThe case is City of Pontiac Police and Fire Retirement System v. Soleno\nTherapeutics, Inc., No. 26-cv-01979.\n\nAbout Kahn Swick & Foti (https://pr.report/l94l), LLC\n\nKSF, whose partners include former Louisiana Attorney General Charles C. Foti,\nJr., is one of the nation's premier boutique securities litigation law firms.\nThis past year, KSF was ranked by SCAS among the top 10 firms nationally based\nupon total settlement value. KSF serves a variety of clients, including public\nand private institutional investors, and retail investors - in seeking\nrecoveries for investment losses emanating from corporate fraud or malfeasance\nby publicly traded companies. KSF has offices in New York, Delaware,\nCalifornia, Louisiana, Chicago, and a representative office in Luxembourg.\n\nTOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services\n\nTo learn more about KSF, you may visit www.ksfcounsel.com.\n\nContact:\n\n(https://app.accessnewswire.com/imagelibrary/b8decb8d-ef1e-4840-b938-8b83908eea3c/image.png)\n\nKahn Swick & Foti, LLC\nLewis Kahn, Managing Partner\nlewis.kahn@ksfcounsel.com\n1-877-515-1850\n1100 Poydras St., Suite 960\nNew Orleans, LA 70163\n\nCONNECT WITH US: Facebook (https://pr.report/l94n) || Instagram\n(https://pr.report/l94o) || YouTube (https://pr.report/l94p) || TikTok\n(https://pr.report/l94q) || LinkedIn (https://pr.report/l94r)\n\nSOURCE: Kahn Swick & Foti, LLC\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/soleno-therapeutics-24-hour-deadline-alert-kahn-swick-and-foti-l-1163731)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-05-04T23:00:00.975600402Z","server_sent_at_ms":1777935600975},"received_at":"2026-05-04T23:00:01.036Z","source_url":"https://www.accessnewswire.com/newsroom/en/business-and-professional-services/soleno-therapeutics-24-hour-deadline-alert-kahn-swick-and-foti-l-1163731"},"analysis":{"id":"14665","press_release_id":"19986","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Kahn Swick & Foti, LLC reminded Soleno Therapeutics investors of a May 5, 2026 deadline to file lead plaintiff applications in a securities class action lawsuit.\n\nThe lawsuit alleges that the company failed to disclose material safety risks related to DCCR, its product for Prader-Willi syndrome, during the class period from March to November 2025.\n\nThis release is a plaintiff-firm solicitation; no new disclosures have been made by the company itself.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{},"quotedText":"remind investors that they have until May 5, 2026 to file lead plaintiff applications","namedEntities":{"people":[{"name":"Lewis Kahn","role":"Managing Partner"},{"name":"Charles C. Foti, Jr.","role":"Partner, former Attorney General of Louisiana"}],"products":["DCCR"],"companies":[{"name":"Kahn Swick & Foti, LLC","relationship":"plaintiff law firm"},{"name":"Soleno Therapeutics, Inc.","ticker":"SLNO","relationship":"target"}],"dollarAmounts":[{"amount":"$100,000","context":"investor loss threshold"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Kahn Swick & Foti, LLC. No new disclosure from the issuer; no certified class, no settlement. Boilerplate lead-plaintiff-deadline reminder."},"tickerRelevance":{"others":[],"primary":"SLNO"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Kahn Swick & Foti, LLC reminded Soleno Therapeutics investors of a May 5, 2026 deadline to file lead plaintiff applications in a securities class action lawsuit.\n\nThe lawsuit alleges that the company failed to disclose material safety risks related to DCCR, its product for Prader-Willi syndrome, during the class period from March to November 2025.\n\nThis release is a plaintiff-firm solicitation; no new disclosures have been made by the company itself.","key_figures":{},"named_entities":{"people":[{"name":"Lewis Kahn","role":"Managing Partner"},{"name":"Charles C. Foti, Jr.","role":"Partner, former Attorney General of Louisiana"}],"products":["DCCR"],"companies":[{"name":"Kahn Swick & Foti, LLC","relationship":"plaintiff law firm"},{"name":"Soleno Therapeutics, Inc.","ticker":"SLNO","relationship":"target"}],"dollarAmounts":[{"amount":"$100,000","context":"investor loss threshold"}]},"model_name":"glm-4.7","prompt_hash":"sha256:a2703c5a1b5285fe","schema_hash":"sha256:1f8af1196c7db48c","created_at":"2026-05-04T23:02:03.052Z","global_importance":15,"audience_relevance":10,"importance_components":{"eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":47970,"modelName":"glm-4.7"}}